Baiyunshan Pharmaceutical boosts H1 R&D spending over 20% to fuel innovation
Guangzhou Baiyunshan Pharmaceutical Holdings reports a year-on-year increase of more than 20 percent in research and development expenditures in the first half of 2026. Guangzhou Baiyunshan Pharmaceutical Holdings, a subsidiary…